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BACKGROUND: Donor-specific antibodies (DSAs) to
HLA antigens can cause acute antibody-mediated rejec-
tion (AMR) after kidney transplantation (Txp). Therapeu-
tic plasma exchange (TPE) has been used for AMR
treatment; however, DSA reduction rates are inconsis-
tent. We investigated DSA reduction rates by HLA
specificity and clinical outcome.
STUDY DESIGN AND METHODS: Sixty-four courses
of TPE for 56 kidney Txp recipients with high DSA were
investigated. Dates of TPE procedures and Txp,
patients’ age, sex, race, creatinine (Cr), and mean fluo-
rescent intensity (MFI) of DSA were retrieved. MFI
reduction rate after one to three TPE and four to six
TPE procedures were calculated by HLA DSA specific-
ity in each patient, and the mean reduction rates were
compared. The relationship of TPE treatment, MFI or Cr
improvement rate, and graft age was also investigated.
RESULTS: Patients received a mean 6.0 TPE proce-
dures. Most received intravenous immunoglobulin after
TPE and immunosuppressives. Forty-two cases
(65.6%) had DSA to HLA Class I and 54 cases (84.4%)
to Class II, including 32 cases (50.0%) to both. Mean
MFI reduction rates after one to three TPE and four to
six TPE procedures were 25.7 and 37.1% in HLA Class
I, 25.1 and 34.2% in Class II, and 14.3 and 19.9% in
DR51-53. The mean Cr improvements at the end of
TPE and 3 and 6 months after TPE were 3.41, −0.37,
and −0.72%, respectively.
CONCLUSION: Six TPE procedures decreased DSA
more than three TPE procedures, but reduction rate
was lower by the second three TPE procedures than
the first three TPE procedures. Although the mean Cr
improvement was minimal, the treatment has good
potential to stop further deterioration of kidney function.
Better Cr improvement rate is correlated with the
graft age.
D
onor-specific antibodies (DSAs) to HLA anti-
gens can cause acute antibody-mediated
rejection (AMR) after kidney transplantation
(Txp). In the past 20 years, high-dose pooled
human intravenous immunoglobulin (IVIG) or therapeu-
tic plasma exchange (TPE) followed by low-dose IVIG has
been used to decrease DSA, immune complexes, or
cytokines for pre-Txp desensitization to increase donor
availability and to prevent hyperacute AMR. There have
been many reports of successful HLA/ABO-incompatible
kidney Txp with preoperative treatment by TPE followed
by IVIG. AMR may be treated similarly, although contro-
versy exists as to the number and timing of TPE and IVIG
infusions. Recently, there have been significant advances
with the technology to detect DSA. Multiplexed bead-
based assays utilizing flow cytometric analysis are much
more sensitive than previously widely used complement-
dependent cytotoxicity method and allow for accurate
determination of HLA DSA specificity and strength.
ABBREVIATIONS: AMR = antibody-mediated rejection;
Cr = creatinine; DSA(s) = donor-specific antibody(-ies);
TPE = therapeutic plasma exchange; t-point = time point (when
followed by a number); Txp = transplantation.
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However, there are limited and inconsistent data
regarding the efficacy of DSA reduction byTPE followed by
IVIG, and the outcomes are uncertain for AMR treatment
with TPE. The reduction rates of DSAs widely vary
between patients and between DSA specificity. Zachary
and colleagues1 reported that the elimination rates of all
DSA byTPE and IVIG in pre-Txp desensitization are 75.6%
for HLA Class I, 60.0% for Class II, and 20% for DR51-53.
However, pre-Txp desensitization and post-Txp AMR
treatment are the TPE applications for different clinical
conditions and DSA responses to TPE may be very differ-
ent. Preventing post-Txp hyperacute AMR by reducing
DSA is the most important purpose for treatment on pre-
operative desensitization. On the other hand, kidney
function recovery associated with DSA reduction is the
goal for post-Txp AMR treatment. To better define optimal
treatment strategy for AMR, we retrospectively investi-
gated our experience with DSA reduction rate by HLA
specificities and clinical outcome in post–renal Txp
patients with AMR who underwent TPE followed by IVIG.
MATERIALS AND METHODS
Eighty-one courses of TPE were administered in 72 kidney
Txp recipients for positive DSA between January 2009 and
September 2012 at the University of Michigan Health
System. Sixteen cases were excluded due to a lack of serial
anti-HLA DSA determinations, an absence of HLA DSA
(mean fluorescence intensities [MFIs] were <700 on all
DSA reports), or an invasive procedure performed during
the course of TPE treatments. A total of 64 treatment
courses (cases) in 56 patients were investigated.
The patients underwent TPE treatment utilizing a
uniform AMR protocol for kidney Txp consisting of one-
plasma-volume exchange with 5% albumin replacement
every other day for up to six procedures followed by
100 mg/kg sucrose-free isosmolar IVIG and 500 mg/kg
after the last TPE. When a patient received an invasive
procedure, such as renal biopsy, within 5 days before the
first TPE, 5 to 10 mL/kg plasmawas used as a replacement
in addition to 5% albumin until 5 days after the procedure.
A quantity of 500 mg/day methylprednisolone for 3 days
was given if the patient did not require anti-thymocyte
globulin for cellular rejection (no cellular rejection, bor-
derline or Banff Classification 1A cellular rejection). If the
patient had Banff Classification 2B or greater cellular
rejection or steroid-resistant cellular rejection, the patient
received 1.5 mg/kg anti-thymocyte globulin daily
(maximumof 150 mg) for 7 to 10 days. All patients were on
one or more kinds of immunosuppressives (steroid,
mycophenolic acid mofetil, tacrolimus, cyclosporine, or
rituximab) before and after the TPE treatments in the
study period.
All patientswere tested for antibodies toHLA-A,B,Cw,
DR,DQ,andDP.Thesewere testedbyLuminex-based tech-
nology (Luminex, Luminex Corp., Austin, TX) using mul-
tiple HLA antigen-coated beads followed by single HLA
antigen–coated beads. The strength of DSAs was reported
as MFI, and MFI of less than 700 was considered as nega-
tive. For this analysis, we recorded negative MFI as 700.
Dates of TPE procedures were retrieved from the elec-
tronic medical record and MFI of all DSAs were from the
tissue typing laboratory information system. Recorded
data included patient age, date of Txp, and available cre-
atinine (Cr) level on each day of TPE and at 3 months
(within ±2 weeks) and at 6months (within ±1month) after
the last TPE. The result of kidney biopsy was recorded.
However, biopsy results were not considered for analysis
since the histologic definition of AMR changed over the
study period. Pretreatment MFI for each patient was the
DSA result prior and closest to the first TPE procedure,
within 5 days. Subsequent blood samples for DSA testing
were drawn immediately before the third and sixth or
the last TPE procedures to minimize the effect of IVIG on
DSA results.
DSA results after the first, second, and third TPE pro-
cedures were grouped as one to three TPE procedures and
that after the fourth, fifth, and the sixth TPE procedures
was grouped as four to six TPE procedures.We designated
time point (t-point) 0 as pretreatment, t-point 1 as after
one to three TPE procedures, and t-point 2 as after four to
six TPE procedures. The MFI reduction rate of each HLA
specificity for each patient was calculated based on pre-
treatment MFI, grouped as above. DSA specificities
DR51-53 were analyzed separately from other DR speci-
ficities due to their complexity of antigen, lower expres-
sion than the others, and a previous observation of higher
persistence after TPE.1 Routine DSA testing to HLA Class
II-DP started during the study period; therefore, the
number of patients with DP DSA was smaller than that for
other HLA specificities.
We investigated the relationship between the age of
the transplanted kidney (graft age, in days) and MFI
reduction rate of eachDSA inHLAClass I and Class II after
four to six TPE procedures (t-point 2). We grouped the
cases into six categories, MFI reduction rates of not more
than 0, 0 to 20, 20 to 40, 40 to 60, 60 to 80, and more than
80%, in each HLA class, and analyzed the corresponding
median graft age in each group. We also grouped cases
into two groups, MFI reduction rates of less than 60% and
more than 60%, in each HLA class, and analyzed the rela-
tion to graft age.
We also investigated the relationship between the
graft age and Cr improvement rate from available Cr
immediately after the last TPE procedure (post-TPE),
within 2 weeks of 3 months, and within 1 month of 6
months after the last TPE treatment in each case. Cr
improvement rates were calculated based on Cr level
within few days before the first TPE procedure started. In
our facility, we treat patients who have subclinical AMR
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and high DSA or evidence of AMR on biopsy but normal
Cr. For Cr improvement analysis, we excluded cases which
had Cr of not more than 1.1 mg/dL at the time TPE pro-
cedure started and also during the observation period of 6
months from analysis because a Cr change within the ref-
erence range is not a clinical improvement. We grouped
cases into six categories, Cr improvement rates of not
more than 0, 0 to 20, 20 to 40, 40 to 60, 60 to 80, and more
than 80% and analyzed the corresponding mean or
median graft age in each group.We also grouped cases by
graft age of notmore than 1 year andmore than 1 year and
analyzed the Cr improvement rate for post-TPE, 3 and 6
months after the last TPE procedure.
We investigated the relationship of Cr improvement
rate to duration of kidney dysfunction, calculated as the
time in days between the datewith last baseline Cr and the
date of the first TPE procedure. The baseline Cr was set as
normal Cr (≤1.1 mg/dL) for a patient whose Cr once had
been not more than 1.1 mg/dL after the Txp or the last
stable nadir Cr when the patient had never had normal Cr
after the Txp. We grouped the cases into six categories by
the same Cr improvement rate as above and analyzed the
correspondingmean or median duration of graft dysfunc-
tion. We excluded cases with Cr levels of not more than
1.1 mg/dL in the observation period.
Frequencies were compared using chi-square tests.
MFI data were not normally distributed and were com-
pared using nonparametric Kruskal-Wallis and Wilcoxon
signed-rank tests. Normally distributed Cr data were com-
pared using t tests and Shapiro-Wilk test. Statistical analy-
ses were performed using computer software (SYSTAT 13,
Cranes Software International, Bangalore, India).
RESULTS
We identified 64 cases involving 56 patients (four patients
were treated twice, two patients were treated 3 times).
Twenty-nine patients were male (51.8%), and 27 patients
were female (48.2%). Thirty-eight patients were Caucasian
(67.9%), 13 patients were African American (23.2%), one
patient was Asian (1.8%), and four patients were other
races (7.1%). The mean age at the time of initiation of TPE
was 39 (range, 11-70) years old. Patients received on
average six procedures (range, two to 11).
A total of 214DSAswere identifiedamong the64 cases.
Ten cases (15.6%) had DSAs to only HLA Class I, 22 cases
(34.4%) to only Class II, and 32 cases (50.0%) to both Class
I andClass II. A total of 42 cases (65.6%) developedDSAs to
Class I and a total of 54 cases (84.4%) developed DSAs to
Class II. DSAs against HLA A, B, C, DR, DR51-53, DQ, and
DP were found in 30 (46.9%), 23 (35.9%), 16 (25.0%), 31
(48.4%), 21 (32.8%), 35 (54.7%), and 10 (15.6%) cases,
respectively (Table 1). SignificantlymoreDSAs hadClass II
specificity (129, 60.3%) than Class I (85, 39.7%; p < 0.001).
HLADQandDR51-53 antibodies had higherMFI on initial
presentation than other specificities (Fig. 1, p < 0.001).
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Fig. 1. Distribution of pretreatment DSA MFI values by HLA
specificity.
TABLE 1. Distribution of DSA specificities among all patients
HLA class I II
Number of cases 42 (65.6%) 54 (84.4%)
Number of DSAs 85 (39.7%) 129 (60.3%)
Median MFI 5,978.5 6,068.0
HLA specificity A B C DR* DR51-53 DQ DP
Number of
cases
30 (46.9%) 23 (35.9%) 16 (25.0%) 31 (48.4%) 21 (32.8%) 35 (54.7%) 10 (15.6%)
Number of
DSAs
37 (17.3%) 29 (13.6%) 19 (8.9%) 36 (16.8%) 22 (10.3%) 56 (26.2%) 15 (7.0%)
Median MFI 2,583.0 1,082.0 1,407.0 3,050.000 5,978.5 11,382.0 2,586.0
* HLA DR specificities excluding DR51, DR52, and DR53.
PLASMAPHERESIS EFFECT ON HLA SPECIFICITY
Volume **, ** ** TRANSFUSION 3Volume 55, April 2015 TRANSFUSION 729
I I I I
We compared the MFI values at each time point.
Although MFI values were not normally distributed, the
percent reduction values were normally distributed
(p < 0.005). Table 2 shows the mean percent MFI reduc-
tion rate based on MFI values on t-point 0. Reductions
were statistically significant for all specificities. However,
we found that MFI reduction rate between t-point 1 and
2 based on MFI value at t-point 1 was much lower than
that between t-point 0 and 1 for some
specificities (Table 3). HLA Class I DSAs
continued to decrease between t-points
1 and 2, but HLA Class II DSAs did not.
Statistically significant differences in
reduction between t-points 1 and 2were
seen for HLA A, B, and DP specificities,
but not for HLA C, DR51-53, other DR,
or DQ.
The mean graft age at the time of
first TPE was 1286.2 days (range, 2-6547
days). The graft age grouped into six
groups based on MFI reduction rate in
HLA Class I and II at t-point 2 is shown
in Fig. 2. There was no significant differ-
ence in MFI reduction rate and the graft
age for both HLA Class I and II
(p > 0.05). When MFI reduction rates at
t-point 2 were grouped as less than 60%
andmore than 60%, there is a significant
difference (p = 0.023 in HLA Class I,
p = 0.033 in HLA Class II; Fig. 3).
In the Cr improvement analysis,
seven cases out of 64 cases were
excluded because of normal Cr level at
all observation time points. In 57 total
cases, Cr data were available in all 57
cases for pre-TPE, in 57 cases for post-
TPE, in 50 cases at 3 months after the
last TPE, and in 43 cases at 6 months
after the last TPE.
The overall mean Cr improvement
rate was 3.4% (from −118.0% to 67.2%)
at post-TPE, −0.37% (from −125.6% to
86.2%) at 3 months, and −0.72% (from
−94.1% to 82.8%) at 6months. Themean
Cr improvement rates for the patients
who received kidney Txp within 1 year
before the initiation of AMR treatment
at post-TPE and 3 and 6 months were
6.76, 6.09, and 6.02%, respectively, and
for the patients who received kidneyTxp
more than 1 year after the initiation of
AMR treatment were 1.69, −4.46, and
−4.47%, respectively (Table 4). However,
these differences were not significant
(p > 0.05, Fig. 4).
The mean graft age in six categories
based on Cr improvement rate is shown
in Table 5. The relationship between the
median graft age and Cr improvement
TABLE 2. Mean MFI reduction percent based on MFI before the
initiation of TPE (t-point 0)
HLA I & II
t-point 1 25.3*
t-point 2 35.3*
HLA Class I II
t-point 1 25.7* 25.1*
t-point 2 37.1* 34.2*
HLA Specificity A B C DR51-53 Other DR DQ DP
t-point 1 40.8* 6.9** 25.2** 14.3* 36.8* 22.0** 28.2**
t-point 2 48.6* 27.2* 32.2* 19.9* 39.8* 33.6* 41.6*
* p < 0.005, **p < 0.05.
t-point 1: after one to three TPE treatments.
t-point 2: after four to six TPE treatments.
TABLE 3. Mean MFI reduction rate on t-point 2 from t-point 1 value
MFI reduction at HLA I & II
t-point 2 from
t-point 1 value
2.7*
HLA Class I II
t-point 2 from
t-point 1 value
8.8* −2.3
HLA Specificity A B C DR51-53 Other DR DQ DP
t-point 2 from
t-point 1 value
10.5** 16.3** 3.3 −28.8 8.2 −4.2 14.8**
* p < 0.005, **p < 0.05.
t-point 1: after one to three TPE treatments.
t-point 2: after four to six TPE treatments.
A. HLA Class I antibodies (p>0.05) B. HLA Class II antibodies (p>0.05)
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Fig. 2. Relationship between MFI reduction rate (six groups) and graft age at t-point
2 (after four to six TPE procedures).
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rate in these groups is shown in Fig. 5. Although there is no
significant difference between groups (p > 0.05) at post-
TPE and 3 and 6 months, a trend toward greater Cr
improvement with younger grafts at any t-point is
observed in Table 5.
The mean days of graft dysfunction in six categories
based on Cr improvement rate is shown in Table 6. The
trend toward better Cr improvement in patients with
shorter duration of graft dysfunction is also observed in
this correlation study. The relationship between the
median days of graft dysfunction and Cr improvement
rate in these groups is shown in Fig. 6. There is a signifi-
cant difference between groups at post-TPE (p = 0.037),
but no significant difference at 3 and 6 months (p > 0.05).
DISCUSSION
TPE is the choice for reduction of pathogenic antibodies
before transplant, as well as for treatment of AMR.
However, the reduction rates of DSAs by TPE followed by
IVIG are not consistent, depending on the patient and on
DSA specificity. This variabilitymay be due to difference in
the rate of DSA removal by TPE or in the
rate of rebound. TPE removes all circu-
lating immunoglobulins without regard
to antigen specificity. Therefore, it is
likely that thevariability of overall reduc-
tion rates of each HLA specificity is due
to difference in the rate of rebound.
We found more DSAs to HLA Class
II specificities than to Class I (65.5% to
Class I vs. 84.4% to Class II), which is
somewhat higher than the result of the
report by Zachary and colleagues2
(67.3% vs. 59.2%, respectively). In par-
ticular, we found that DSAs to DQ speci-
ficity was found inmore than 50% of the
patients (Table 1). Zachary and col-
leagues1 also reported elimination of all
DSAs in 53.7% of patients who received
treatment for pre-Txp desensitization.
In our patient population, all DSAs
were eliminated in only five of 64 cases
(7.8%). The desensitization protocol
employed by Zachary and colleagues
and our protocol for AMR are similar.
Notably, the highest DSA level on our
five cases was only 2594 MFI. These
A. HLA Class I antibodies (p=0.023) B. HLA Class II antibodies (p=0.033)
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Fig. 3. Relationship between MFI reduction rate of less than 60% and more than 60%
and graft age at t-point 2 (after four to six TPE procedures).
TABLE 4. Mean Cr improvement rate (%) after the TPE treatment
based on graft age
Cr improvement rate
After
TPE
3 months
after TPE
6 months
after TPE
<1 year after Txp 6.76 6.09 6.02
>1 year after Txp 1.69 −4.46 −4.47
Overall 3.41 −0.37 −0.72
<1 year >1 year
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A. Post-TPE (p>0.05) B. 3 months after the last TPE (p>0.05) C. 6 months after the last TPE (p>0.05)
Fig. 4. Relationship between Cr improvement rate and graft age of less and more than 1 year at t-point 2 (after four to six TPE
procedures).
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differences between pretransplant desensitization and
posttransplant treatment of AMR are explainable by the
presence of active antigens on the transplanted kidney
that may stimulate production of antibodies. This obser-
vation may suggest that post-Txp patients with AMR may
require more aggressive immunosuppression to prevent
rebound than patients for pre-Txp sensitization, such as
higher doses of IVIG after TPE, medications for B-cell or
plasma cell suppression, anti-thymocyte globulin for all
AMR patients to suppress T-cell–dependent B-cell
response, and a combination of those. This hypothesis is
supported by a report by Ramos and coworkers,3 which
showed that the combination therapy targeting multiple
immune response pathways had greater effect in decreas-
ing both mature and memory B cells in spleen.
We observed that DSA reductionwas greater at four to
six TPE procedures than one to three TPE procedures,
although the rate was dependent on specificity. The DSA
reduction rates for Class I and II and DR51-53 specificities
at t-point 2 in our patients were 37.1, 34.2, and 19.9%,
respectively. However, the reduction rate between t-points
1 and2was significantly lower than thatbetween t-points 0
and 1 (25.3% between t-points 0 and 1 vs. 2.7% between
t-points 1 and 2; Tables 2 and 3). This may be because the
medianDSA level was lower at the t-point 1 than at t-point
0. As Zachary and coworkers1 reported, DSA strength at
initiationof treatmentmight have an impact onDSAelimi-
nation. We observed that HLA C, DR51-52, other DR, and
DQspecificities didnot showsignificant differences inMFI
between t-points 1 and 2. Furthermore, we observed
increases in HLA DR51-53, DQ and overall HLA II indicat-
ing that DSA rebound is higher during four to six TPE
procedures in these specificities. This observation may
suggest that continuation of TPE beyond an optimal
number of procedures is detrimental for some DSA
specificities.
The phenomenon of antibody rebound after TPE is
well described. Dau4 reported a significant increase in
B-cell percentage in peripheral blood lymphocyte popu-
lations with TPE, which leads to increasing antibody
production. We hypothesize that at least four other
mechanisms may account for rebound in the setting of
TPE for AMR, as follows: 1) Naïve cells may be activated by
TPE.When naïve cells are activated, they can be sensitized
by existing antigens on transplanted kidney leading to
production of de novo DSAs. Active antigens sensitize
naïve cells more than inactive antigens, and our data on
post-Txp patients with active antigen show lower overall
DSA reduction rates than pre-Txp patients. 2) Memory
B cells may be activated by TPE and produce more DSAs.
Paglieroni and coworkers5 reported B cells are more acti-
vated 7 to 9 days after TPE. Although Sadeghi and col-
leagues6 showed that T and B lymphocyte counts were
decreased immediately afterTPE, the timing of thesemea-
surements may be too early to prove activation of cells.
Additionally, since their TPE procedure used a filter
method that is different from the centrifugation method
we utilized, the rate of T- and B-cell activation may be
different in our study. 3) Negative feedback on DSA-
producing B cells is decreased by lowered DSA level
leading to more DSA production. TPE removes existing
DSAs and IVIG decreases DSA production. Plasma cells
may not be affected by TPE and immunomodulatory
medications as shown by Ramos and colleagues.3 Mayer
and coworkers7 reported IVIG inhibits T-cell–dependent
TABLE 5. Mean graft age (days) at the time of
initiation of TPE treatment on Cr improvement
rates
Cr improvement
rate (%) After TPE
3 months
after TPE
6 months
after TPE
≤0 1462.5 1465.5 1813.2
0-20 1461.6 1340.2 1152.2
20-40 1047.3 1241.7 55.0
40-60 321.7 480.5
60-80 7.0 10.0
>80 7.0 7.0
A. Post-TPE (p>0.05) B. 3 months after the last TPE (p>0.05) C. 6 months after the last TPE (p>0.05)
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Fig. 5. Relationship between Cr improvement rate and graft age (six groups).
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B-cell proliferation and differentiation, and Tawfik and
colleagues8 suggested that IVIG inhibits T-cell prolifera-
tion leading to inhibition of T-cell–dependent B-cell
proliferation. Therefore, when DSA levels are high, the
immunoglobulin production from B cells is suppressed.
However, when DSA levels are reduced by TPE and the
down regulation effect of IVIG, negative feedback is
decreased. The net result may be that B cells produce
more DSAs after the effect of IVIG has diminished. 4)
Antigens on damaged kidney tissue release bound anti-
bodies (DSAs). Early in AMR, antigens on healthy kidney
tissue absorb tissue-specific antibodies. At this point, cir-
culating DSA level may be paradoxically low. However,
when the graft tissue is damaged in AMR, the bound anti-
bodies may be released into circulation leading to high
DSA detection.
The trend toward better Cr improvement rate in
patients with shorter graft age is seen in Tables 4 and 5.
The patients with Cr improvement rate of more than 60%
at any time point received their kidney transplants within
10 days before the treatment. In contrast, patients who
received Txp 3 years or more before TPE treatment had
overall Cr improvement rates of less than 20%. Further
correlation study between the duration of graft dysfunc-
tion and Cr improvement showed a significant relation-
ship between better Cr improvement and shorter duration
of graft dysfunction (Fig. 6). The older grafts most likely
had slow deterioration of graft function over a longer
period in our study, possibly due to chronic rejection. This
observation underscores the importance of early initia-
tion of AMR treatment. It is difficult to detect deterioration
of kidney function early long after the Txp because most
patients’ post-Txp follow-up visits are usually less fre-
quent over the time. Furthermore, the deterioration of
graft function, and resultant Cr increase, may be too slow
to trigger the treatment. Therefore, by the time that high
DSA levels are detected, significant allograft injury may
already have occurred, and the damage may be irrevers-
ible at the time of treatment.
The importance of early initiation of treatment is also
highlighted by our correlation study between MFI
improvement rate and graft age (Fig. 3) showing younger
grafts had higher MFI improvement rate. It strongly sug-
gests that early initiation of treatment is more effective to
decrease MFI.
Assessing the correlation between Cr improvement
rate and DSA reduction rate is problematic since 54 cases
(84.4%) had multiple DSA specificities, and the role of
individual DSA specificity in the causation of AMR in each
patient is difficult to determine. For example, even though
one high DSA specificity in a patient who has multiple
types of high DSAs is significantly reduced by TPE treat-
ment, Cr may not improve if that particular specificity is
not playing a main role in AMR. Additionally, most of our
patients had some degrees of cellular rejection and prob-
ably chronic rejection in older grafts, which may have
some impact on the Cr result.
Overall, the mean Cr improvement rate was minimal
at any point (Table 4) in our study. However, we observed
that the Cr remained stable over 6 months of follow-up.
Thus, TPE treatmentmay be able to halt further functional
deterioration in older grafts for at least 6 months.
Recently, several studies have suggested that non-
HLA antibodies may be responsible for some cases of
AMR. In addition to improved sensitive HLA antibody
detection, a test is available for the detection of C1q
TABLE 6. Mean days of graft dysfunction at the
time of initiation of TPE treatment on Cr
improvement rates
Cr improvement
rate (%) After TPE
3 months
after TPE
6 months
after TPE
≤0 548.0 511.5 499.7
0-20 319.0 411.3 491.0
20-40 547.2 563.3 55.0
40-60 72.3 106.5
60-80 7.0 10.0
>80 7.0 7.0
A. Post-TPE (p=0.037) B. 3 months after the last TPE (p>0.05) C. 6 months after the last TPE (p>0.05)
<0 0-20 20-4040-6060-80
Cr improvement after treatment
0
1,000
2,000
3,000
D
ay
s 
fr
om
 n
or
m
al
/b
as
el
in
e 
C
r
<0 0-20 20-40 40-60 60-80 >80
Cr improvement at 3 months
0
1,000
2,000
3,000
D
ay
s 
fr
om
 n
or
m
al
/b
as
el
in
e 
C
r
<0 0-20 20-40 >80
Cr improvement at 6 months
0
1,000
2,000
3,000
D
ay
s 
fr
om
 n
or
m
al
/b
as
el
in
e 
C
r
Fig. 6. Relationship between Cr improvement rate and the duration of graft dysfunction.
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binding HLA antibodies,9-11 non-HLA DSAs including
endothelial precursor cell antibodies, and polymorphic
MHC Class I–related Chain A antibodies.12-15 Other non-
HLA antibodies and autoantibodies, such as antibodies to
anti-angiotensin IIType 1 receptor, anti-endothelin recep-
tor,16 vimentin, tubulin, myosin, collagen,12 nucleolin,17 or
laminin18 may also play important roles12 similar to the
mechanisms to hemolysis caused by auto antibodies to
RBCs. A recently available C1q binding HLA antibody
detection may assist in the determination of which DSA
specificities among multiple DSAs are causing AMR in
future. However, the complexity of the test method and
lower sensitivity to low titer of antibodies are limitations of
the currently available tests.
Novel therapies for AMR, possibly in addition to TPE
and IVIG are now becoming available. These include
newer medications such as anti-CD20 for B cells
(rituximab),19,20 proteasome inhibitors leading to plasma
cell apoptosis (bortezomib21-24), anti-interleukin-2 recep-
tor antibodies (daclizumab,25,26 basiliximab27,28), and
anti-CD52 (alemtuzumab25,29). Anti-complement therapy
(eculizumab,19,30,31 recombinant human C1 esterase
inhibitor19,30,32-34) may also be possibilities in the future to
interfere with the complement cascade initiated by
antigen–antibody complexes, which has a potential to
prevent complement-mediated cell damage. However,
the effect of anti-complement therapy on AMR has not
been well studied to date. Apheresis technology utilizing
adsorption columns that are available in Europe and Asia
mayhaveapotential to reducespecificDSAsselectively.35,36
However, the efficacy and safety of these columns on
AMR is unknown, and the availability and the high cost of
development and production of the column in the United
States may be significant limitations. Further investiga-
tions of these potential novel therapies for AMR are
needed.
In summary, we report the efficacy of TPE followed by
IVIG in reducing DSAs by HLA specificity in the treatment
of AMR after kidney Txp. The treatment reduced DSA
levels by 25.3 and 35.5% after three and six TPE proce-
dures, respectively. However, theDSA reductionwasmuch
less marked after three TPE procedures. HLA Class I DSAs
were reduced slightly more than Class II DSAs with least
reduction rate of DSAs to DR51-53. Cr improvement rates
were minimal with treatment. However, we found
improvement of graft function for younger grafts and sta-
bilization of older grafts for 6monthswith AMR treatment.
Our data also emphasize the importance of early initiation
of treatment.
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